DK0892789T4
(da)
|
1996-04-12 |
2010-04-06 |
Warner Lambert Co |
Irreversible inhibitorer af tyrosin kinaser
|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
TW436485B
(en)
*
|
1997-08-01 |
2001-05-28 |
American Cyanamid Co |
Substituted quinazoline derivatives
|
AU8816298A
(en)
|
1997-08-22 |
1999-03-16 |
Zeneca Limited |
Oxindolylquinazoline derivatives as angiogenesis inhibitors
|
CA2337422C
(en)
|
1998-08-18 |
2010-11-02 |
The Regents Of The University Of California |
Preventing airway mucus production by administration of egf-r antagonists
|
US6184226B1
(en)
|
1998-08-28 |
2001-02-06 |
Scios Inc. |
Quinazoline derivatives as inhibitors of P-38 α
|
SI2253620T1
(sl)
|
1998-09-29 |
2014-06-30 |
Wyeth Holdings Llc |
Substituirani 3-cianokinolini kot inhibitorji protein tirozin-kinaz
|
CN1161352C
(zh)
|
1998-10-08 |
2004-08-11 |
阿斯特拉曾尼卡有限公司 |
喹唑啉衍生物
|
JP3751201B2
(ja)
*
|
1999-02-27 |
2006-03-01 |
ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト |
チロシンキナーゼにより媒介されるシグナル伝達に関する抑制効果を有する4−アミノ−キナゾリン誘導体及びキノリン誘導体
|
CN100408576C
(zh)
*
|
1999-04-21 |
2008-08-06 |
惠氏控股有限公司 |
取代的3-氰基-[1.7],[1.5]和[1.8]-二氮杂萘酪氨酸激酶抑制剂
|
KR100709909B1
(ko)
*
|
1999-06-21 |
2007-04-24 |
베링거 잉겔하임 파르마 게엠베하 운트 코 카게 |
비사이클릭 헤테로사이클, 이를 함유하는 의약 조성물 및 이의 제조방법
|
ATE398120T1
(de)
|
1999-11-05 |
2008-07-15 |
Astrazeneca Ab |
Neue quinazolin-derivate
|
ATE350378T1
(de)
*
|
2000-04-08 |
2007-01-15 |
Boehringer Ingelheim Pharma |
Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
|
US6627634B2
(en)
|
2000-04-08 |
2003-09-30 |
Boehringer Ingelheim Pharma Kg |
Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
|
UA73993C2
(uk)
|
2000-06-06 |
2005-10-17 |
Астразенека Аб |
Хіназолінові похідні для лікування пухлин та фармацевтична композиція
|
EE200200715A
(et)
*
|
2000-06-28 |
2004-08-16 |
Astrazeneca Ab |
Asendatud kinasoliini derivaadid ja nende kasutamine inhibiitoritena
|
RU2267489C2
(ru)
|
2000-08-21 |
2006-01-10 |
Астразенека Аб |
Производные хиназолина, способ их получения и фармацевтическая композиция
|
DE10042060A1
(de)
*
|
2000-08-26 |
2002-03-07 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
US6617329B2
(en)
|
2000-08-26 |
2003-09-09 |
Boehringer Ingelheim Pharma Kg |
Aminoquinazolines and their use as medicaments
|
DE10042062A1
(de)
*
|
2000-08-26 |
2002-03-07 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Hertellung
|
US6403580B1
(en)
|
2000-08-26 |
2002-06-11 |
Boehringer Ingelheim Pharma Kg |
Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them
|
US6656946B2
(en)
|
2000-08-26 |
2003-12-02 |
Boehringer Ingelheim Pharma Kg |
Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
|
US6653305B2
(en)
|
2000-08-26 |
2003-11-25 |
Boehringer Ingelheim Pharma Kg |
Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
|
US6740651B2
(en)
|
2000-08-26 |
2004-05-25 |
Boehringer Ingelheim Pharma Kg |
Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
|
US6939866B2
(en)
|
2000-10-13 |
2005-09-06 |
Astrazeneca Ab |
Quinazoline derivatives
|
AU2001292138A1
(en)
|
2000-10-13 |
2002-04-22 |
Astrazeneca Ab |
Quinazoline derivatives with anti-tumour activity
|
US7019012B2
(en)
|
2000-12-20 |
2006-03-28 |
Boehringer Ingelheim International Pharma Gmbh & Co. Kg |
Quinazoline derivatives and pharmaceutical compositions containing them
|
US6562319B2
(en)
|
2001-03-12 |
2003-05-13 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy
|
DE60229046D1
(de)
|
2001-04-19 |
2008-11-06 |
Astrazeneca Ab |
Chinazolin derivate
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US6924285B2
(en)
|
2002-03-30 |
2005-08-02 |
Boehringer Ingelheim Pharma Gmbh & Co. |
Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
|
US20040044014A1
(en)
|
2002-04-19 |
2004-03-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
|
DE10217689A1
(de)
*
|
2002-04-19 |
2003-11-13 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung
|
DE10221018A1
(de)
|
2002-05-11 |
2003-11-27 |
Boehringer Ingelheim Pharma |
Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
|
MXPA05000403A
(es)
|
2002-07-15 |
2005-07-22 |
Genentech Inc |
Metodos para identificar tumores que responden al tratamiento con anticuerpos contra erbb2.
|
DE60313339T2
(de)
|
2002-07-31 |
2008-01-03 |
Critical Outcome Technologies, Inc. |
Protein tyrosin kinase inhibitoren
|
CN101987871A
(zh)
|
2002-09-27 |
2011-03-23 |
赞科股份有限公司 |
优化的Fc变体及其产生方法
|
AU2003273675A1
(en)
|
2002-10-09 |
2004-05-04 |
Wayne R. Danter |
Protein tyrosine kinase inhibitors
|
US7109337B2
(en)
|
2002-12-20 |
2006-09-19 |
Pfizer Inc |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
ATE458731T1
(de)
|
2002-12-20 |
2010-03-15 |
Pfizer Prod Inc |
Pyrimidin-derivate zur behandlung von anormalem zellwachstum
|
JP2006515871A
(ja)
*
|
2003-01-23 |
2006-06-08 |
ティー.ケイ. シグナル リミテッド |
上皮増殖因子受容体チロシンキナーゼの不可逆阻害剤ならびにその使用
|
US7223749B2
(en)
|
2003-02-20 |
2007-05-29 |
Boehringer Ingelheim International Gmbh |
Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
GB0309850D0
(en)
|
2003-04-30 |
2003-06-04 |
Astrazeneca Ab |
Quinazoline derivatives
|
NZ543234A
(en)
|
2003-05-30 |
2009-04-30 |
Astrazeneca Uk Ltd |
Marker genes and uses thereof to identify cancer patients that will respond to erbb tyrosine kinase inhibitors
|
ES2293251T3
(es)
*
|
2003-06-10 |
2008-03-16 |
F. Hoffmann-La Roche Ag |
Derivados de 1,3,4-triaza-fenaleno y 1,3,4,6-tetraazafenaleno.
|
US8309562B2
(en)
|
2003-07-03 |
2012-11-13 |
Myrexis, Inc. |
Compounds and therapeutical use thereof
|
US7501427B2
(en)
|
2003-08-14 |
2009-03-10 |
Array Biopharma, Inc. |
Quinazoline analogs as receptor tyrosine kinase inhibitors
|
ES2399427T3
(es)
|
2003-08-14 |
2013-04-01 |
Array Biopharma, Inc. |
Análogos de quinazolina como inhibidores de los receptores de la tirosina-quinasa
|
WO2005023315A2
(en)
*
|
2003-09-11 |
2005-03-17 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Radiolabeled anilinoquinazolines and their use in radioimaging and radiotherapy
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US7456189B2
(en)
|
2003-09-30 |
2008-11-25 |
Boehringer Ingelheim International Gmbh |
Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
|
DE10349113A1
(de)
|
2003-10-17 |
2005-05-12 |
Boehringer Ingelheim Pharma |
Verfahren zur Herstellung von Aminocrotonylverbindungen
|
KR101438983B1
(ko)
|
2003-11-06 |
2014-09-05 |
시애틀 지네틱스, 인크. |
리간드에 접합될 수 있는 모노메틸발린 화합물
|
GB0326459D0
(en)
|
2003-11-13 |
2003-12-17 |
Astrazeneca Ab |
Quinazoline derivatives
|
CN101501211A
(zh)
|
2004-03-31 |
2009-08-05 |
综合医院公司 |
测定癌症对表皮生长因子受体靶向性治疗反应性的方法
|
CA2565812C
(en)
|
2004-05-06 |
2012-03-13 |
Warner-Lambert Company Llc |
4-phenylamino-quinazolin-6-yl-amides
|
MXPA06011658A
(es)
|
2004-05-14 |
2006-12-14 |
Pfizer Prod Inc |
Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
|
BRPI0510963A
(pt)
|
2004-05-14 |
2007-11-20 |
Pfizer Prod Inc |
derivados pirimidina para o tratamento do crescimento anormal de células
|
BRPI0510980A
(pt)
|
2004-05-14 |
2007-11-27 |
Pfizer Prod Inc |
derivados de pirimidina para o tratamento do crescimento anormal de células
|
AU2005249490B2
(en)
|
2004-06-01 |
2010-07-29 |
Genentech, Inc. |
Antibody drug conjugates and methods
|
AU2005272993B2
(en)
|
2004-07-15 |
2010-02-11 |
Xencor, Inc |
Optimized Fc variants
|
PL1791565T3
(pl)
|
2004-09-23 |
2016-10-31 |
|
Modyfikowane cysteiną przeciwciała i koniugaty
|
US20070054916A1
(en)
*
|
2004-10-01 |
2007-03-08 |
Amgen Inc. |
Aryl nitrogen-containing bicyclic compounds and methods of use
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
DK2325207T3
(en)
|
2004-11-12 |
2017-06-06 |
Xencor Inc |
Fc variants with altered binding to FcRn
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
ATE501148T1
(de)
|
2004-12-14 |
2011-03-15 |
Astrazeneca Ab |
Pyrazolopyrimidinverbindungen als antitumormittel
|
KR100735639B1
(ko)
*
|
2004-12-29 |
2007-07-04 |
한미약품 주식회사 |
암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
|
US8258145B2
(en)
|
2005-01-03 |
2012-09-04 |
Myrexis, Inc. |
Method of treating brain cancer
|
EP1833482A4
(de)
|
2005-01-03 |
2011-02-16 |
Myriad Genetics Inc |
Verbindungen und ihre therapeutische verwendung
|
CN101141981A
(zh)
|
2005-01-21 |
2008-03-12 |
健泰科生物技术公司 |
Her抗体的固定剂量给药
|
EP2399605A1
(de)
|
2005-02-23 |
2011-12-28 |
Genentech, Inc. |
Ausdehnungszeit einer Krankheitsprogression oder -überlebens bei Krebspatienten
|
AU2006236423B2
(en)
|
2005-04-19 |
2009-12-10 |
Novartis Ag |
Pharmaceutical composition
|
JP2009508918A
(ja)
|
2005-09-20 |
2009-03-05 |
アストラゼネカ アクチボラグ |
癌治療のためのerbB受容体チロシンキナーゼ阻害剤としての4−(1H−インダゾール−5−イル]アミノ)キナゾリン化合物
|
WO2007041635A2
(en)
|
2005-10-03 |
2007-04-12 |
Xencor, Inc. |
Fc variants with optimized fc receptor binding properties
|
US8404697B2
(en)
|
2005-11-11 |
2013-03-26 |
Boehringer Ingelheim International Gmbh |
Quinazoline derivatives for the treatment of cancer diseases
|
EP2021316A1
(de)
*
|
2006-05-26 |
2009-02-11 |
Abbott Laboratories |
Polokinasenhemmer
|
ME01786B
(me)
|
2006-08-14 |
2014-09-20 |
Xencor Inc |
Optimizovana antitela usmerena na cd19
|
US20100008910A1
(en)
|
2006-09-12 |
2010-01-14 |
John Chant |
Methods and compositions for the diagnosis and treatment of cancer
|
NZ576065A
(en)
|
2006-09-18 |
2011-12-22 |
Boehringer Ingelheim Int |
Method for treating cancer harboring egfr mutations
|
EP1921070A1
(de)
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
|
US8138191B2
(en)
|
2007-01-11 |
2012-03-20 |
Critical Outcome Technologies Inc. |
Inhibitor compounds and cancer treatment methods
|
MX2009007610A
(es)
|
2007-02-06 |
2009-07-24 |
Boehringer Ingelheim Int |
Heterociclicos biciclicos, medicamentos que contienen estos compuestos, su utilizacion y procedimientos para su preparacion.
|
WO2008109440A2
(en)
|
2007-03-02 |
2008-09-12 |
Genentech, Inc. |
Predicting response to a her dimerisation inhibitor based on low her3 expression
|
CA2693053C
(en)
|
2007-05-30 |
2021-01-05 |
Xencor, Inc. |
Methods and compositions for inhibiting cd32b expressing cells
|
CA3006428A1
(en)
|
2007-06-08 |
2008-12-18 |
Genentech, Inc. |
Gene expression markers of tumor resistance to her2 inhibitor treatment
|
CA2698928A1
(en)
*
|
2007-09-28 |
2009-04-09 |
Absolute Science, Inc. |
Compounds and methods for treating zinc matrix metalloprotease dependent diseases
|
US8513233B2
(en)
|
2007-10-11 |
2013-08-20 |
Shanghai Institute Of Materia Medica, Cas |
Pyrimidinyl-propionic acid derivatives and their use as PPAR agonists
|
EP3825329A1
(de)
|
2007-12-26 |
2021-05-26 |
Xencor, Inc. |
Fc-varianten mit veränderter bindung zu fcrn
|
US8466151B2
(en)
|
2007-12-26 |
2013-06-18 |
Critical Outcome Technologies, Inc. |
Compounds and method for treatment of cancer
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
SI2245026T1
(sl)
|
2008-02-07 |
2012-12-31 |
Boehringer Ingelheim International Gmbh |
Spirociklični heterocikli, zdravila, ki vsebujejo te spojine, njihova uporaba in postopek za njihovo pripravo
|
BRPI0912170A2
(pt)
|
2008-05-13 |
2015-10-13 |
Astrazeneca Ab |
composto, forma a, processo para a preparação da mesma, composição farmacêutica, uso de um composto, e, método para tratar um câncer em um animal de sangue quente
|
ES2430590T3
(es)
|
2008-05-14 |
2013-11-21 |
Genomic Health, Inc. |
Predictores de la respuesta de pacientes al tratamiento con inhibidores del receptor del EGF
|
WO2010015522A1
(de)
|
2008-08-08 |
2010-02-11 |
Boehringer Ingelheim International Gmbh |
Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
|
ITMI20082336A1
(it)
*
|
2008-12-29 |
2010-06-30 |
Univ Parma |
Composti inibitori irreversibili di egfr con attivita' antiproliferativa
|
WO2010104406A1
(en)
*
|
2009-03-11 |
2010-09-16 |
Auckland Uniservices Limited |
Prodrug forms of kinase inhibitors and their use in therapy
|
KR20130080871A
(ko)
|
2009-03-20 |
2013-07-15 |
제넨테크, 인크. |
이중특이적 항-her 항체
|
SI2451445T1
(sl)
|
2009-07-06 |
2019-07-31 |
Boehringer Ingelheim International Gmbh |
Postopek za sušenje BIBW2992, njegovih soli in trdnih farmacevtskih formulacij, ki obsegajo to aktivno sestavino
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
EP2473509A4
(de)
*
|
2009-09-02 |
2013-04-17 |
Auckland Uniservices Ltd |
Kinasehemmer, prodrug-formen davon und ihre verwendung in der therapie
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
KR20120103587A
(ko)
|
2009-11-12 |
2012-09-19 |
제넨테크, 인크. |
수상돌기 소극 밀도를 증진시키는 방법
|
CA2781682A1
(en)
|
2009-12-04 |
2011-06-09 |
Genentech, Inc. |
Multispecific antibodies, antibody analogs, compositions, and methods
|
TW201129565A
(en)
|
2010-01-12 |
2011-09-01 |
Hoffmann La Roche |
Tricyclic heterocyclic compounds, compositions and methods of use thereof
|
SI2536748T1
(sl)
|
2010-02-18 |
2014-12-31 |
Genentech, Inc. |
Nevrogulinski antagonisti in njihova uporaba pri zdravljenju raka
|
WO2011107664A1
(en)
|
2010-03-04 |
2011-09-09 |
Hospital District Of Southwest Finland |
Method for selecting patients for treatment with an egfr inhibitor
|
CA2793024A1
(en)
|
2010-03-17 |
2011-09-22 |
F. Hoffmann-La Roche Ag |
Imidazopyridine compounds, compositions and methods of use
|
MX341925B
(es)
|
2010-03-29 |
2016-09-07 |
Zymeworks Inc |
Anticuerpos con funcion efectora suprimida o mejorada.
|
CA2999435A1
(en)
|
2010-04-01 |
2011-10-06 |
Critical Outcome Technologies Inc. |
Compounds and method for treatment of hiv
|
CA2793892A1
(en)
|
2010-04-16 |
2011-10-20 |
Elizabeth Punnoose |
Foxo3a as predictive biomarker for pi3k/akt kinase pathway inhibitor efficacy
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
US20120089541A1
(en)
|
2010-08-31 |
2012-04-12 |
Genentech, Inc. |
Biomarkers and methods of treatment
|
AR082974A1
(es)
|
2010-09-15 |
2013-01-23 |
Hoffmann La Roche |
Derivados de azabenzotiazol, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para tratar enfermedades inflamatorias
|
CA2816957A1
(en)
|
2010-11-07 |
2012-05-10 |
Targegen, Inc. |
Compositions and methods for treating myelofibrosis
|
US9309322B2
(en)
|
2010-11-12 |
2016-04-12 |
Scott & White Healthcare (Swh) |
Antibodies to tumor endothelial marker 8
|
BR112013011520A2
(pt)
|
2010-11-19 |
2019-09-24 |
Hoffmann La Roche |
pirazolo piridinas e pirazolo piridinas e seu uso como inibidores de tyk2
|
CN102485735B
(zh)
*
|
2010-12-02 |
2014-09-24 |
东莞南方医大代谢医学研发有限公司 |
6-果糖氨-4-芳胺基喹唑啉衍生物及其用途
|
WO2012085176A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
|
SG193291A1
(en)
|
2011-03-04 |
2013-10-30 |
Newgen Therapeutics Inc |
Alkyne substituted quinazoline compound and methods of use
|
WO2012122513A2
(en)
|
2011-03-10 |
2012-09-13 |
Omeros Corporation |
Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution
|
CN102918029B
(zh)
*
|
2011-05-17 |
2015-06-17 |
江苏康缘药业股份有限公司 |
4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
|
WO2013007765A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Fused tricyclic compounds for use as inhibitors of janus kinases
|
WO2013007768A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
|
BR112014003237A2
(pt)
|
2011-08-12 |
2017-04-25 |
Hoffmann La Roche |
compostos de indazol, composições e métodos de uso
|
WO2013025446A2
(en)
|
2011-08-12 |
2013-02-21 |
Omeros Corporation |
Anti-fzd10 monoclonal antibodies and methods for their use
|
BR112014003431A2
(pt)
|
2011-08-17 |
2017-06-13 |
Genentech Inc |
anticorpo, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, agente farmacêutico, uso do anticorpo, método de tratamento de um indivíduo que tem câncer e método de aumento de tempo para recorrência de tumor
|
WO2013041539A1
(en)
|
2011-09-20 |
2013-03-28 |
F. Hoffmann-La Roche Ag |
Imidazopyridine compounds, compositions and methods of use
|
KR20140100474A
(ko)
*
|
2011-11-21 |
2014-08-14 |
바스프 에스이 |
N-치환된 1h-피라졸-5-카르복실레이트 화합물 및 그의 유도체를 제조하는 방법
|
AU2012346540C1
(en)
|
2011-11-30 |
2019-07-04 |
Genentech, Inc. |
ErbB3 mutations in cancer
|
CN104379602B
(zh)
|
2012-03-08 |
2017-05-03 |
哈洛齐梅公司 |
具有条件活性的抗表皮生长因子受体抗体及其使用方法
|
BR112014024017A8
(pt)
|
2012-03-27 |
2017-07-25 |
Genentech Inc |
Métodos de tratamento de um tipo de câncer, de tratamento do carcinoma, para selecionar uma terapia e para quantificação e inibidor de her3
|
CN104994879A
(zh)
|
2013-02-22 |
2015-10-21 |
霍夫曼-拉罗奇有限公司 |
治疗癌症和预防药物抗性的方法
|
BR112015021423A2
(pt)
|
2013-03-06 |
2017-07-18 |
Genentech Inc |
métodos de tratamento de câncer, de células de câncer e de câncer resistente a antagonista de egfr, métodos de aumento da sensibilidade e da eficácia de tratamento de câncer e métodos de atraso, de tratamento de indivíduos com câncer e de extensão
|
BR112015022545A2
(pt)
|
2013-03-13 |
2017-07-18 |
Constellation Pharmaceuticals Inc |
compostos de pirazolo e os usos disso
|
RU2015139054A
(ru)
|
2013-03-14 |
2017-04-19 |
Дженентек, Инк. |
Способы лечения рака и профилактики лекарственной резистентности рака
|
AU2014239903A1
(en)
|
2013-03-14 |
2015-09-17 |
Genentech, Inc. |
Combinations of a MEK inhibitor compound with an HER3/EGFR inhibitor compound and methods of use
|
KR20150130451A
(ko)
|
2013-03-15 |
2015-11-23 |
제넨테크, 인크. |
암 치료 방법 및 항암제 내성 예방을 위한 방법
|
EP3041474B1
(de)
|
2013-09-05 |
2020-03-18 |
Genentech, Inc. |
Antiproliferative verbindungen
|
SG11201601770YA
(en)
|
2013-09-12 |
2016-04-28 |
Halozyme Inc |
Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
|
TW201605857A
(zh)
|
2013-10-03 |
2016-02-16 |
赫孚孟拉羅股份公司 |
Cdk8之醫療性抑制劑及其用途
|
US20150147333A1
(en)
|
2013-10-18 |
2015-05-28 |
Genentech, Inc. |
Anti-rspo antibodies and methods of use
|
KR20240017102A
(ko)
|
2013-12-17 |
2024-02-06 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 탁산을 이용한 암 치료 방법
|
KR20160099092A
(ko)
|
2013-12-17 |
2016-08-19 |
제넨테크, 인크. |
Ox40 결합 효능제 및 pd-1 축 결합 길항제를 포함하는 조합 요법
|
US9242965B2
(en)
|
2013-12-31 |
2016-01-26 |
Boehringer Ingelheim International Gmbh |
Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
|
JP2017516458A
(ja)
|
2014-03-24 |
2017-06-22 |
ジェネンテック, インコーポレイテッド |
c−met拮抗剤による癌治療及びc−met拮抗剤のHGF発現との相関
|
MX2016012779A
(es)
|
2014-03-31 |
2017-04-27 |
Genentech Inc |
Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40.
|
PT3126394T
(pt)
|
2014-03-31 |
2019-12-19 |
Hoffmann La Roche |
Anticorpos anti-ox40 e métodos de utilização
|
CN107074823B
(zh)
|
2014-09-05 |
2021-05-04 |
基因泰克公司 |
治疗性化合物及其用途
|
WO2016044694A1
(en)
|
2014-09-19 |
2016-03-24 |
Genentech, Inc. |
Use of cbp/ep300 and bet inhibitors for treatment of cancer
|
EP3204379B1
(de)
|
2014-10-10 |
2019-03-06 |
Genentech, Inc. |
Pyrrolidinamid-verbindungen als histondemethylase-inhibitoren
|
US20160160290A1
(en)
|
2014-11-03 |
2016-06-09 |
Genentech, Inc. |
Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
|
EP3215850B1
(de)
|
2014-11-03 |
2019-07-03 |
F. Hoffmann-La Roche AG |
Tests zum nachweis von te-zell-immununtergruppen und verfahren zur verwendung davon
|
US20160152720A1
(en)
|
2014-11-06 |
2016-06-02 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and tigit inhibitors
|
MA40943A
(fr)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
|
CN107108613B
(zh)
|
2014-11-10 |
2020-02-25 |
基因泰克公司 |
布罗莫结构域抑制剂及其用途
|
MA40940A
(fr)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
|
AU2015350242A1
(en)
|
2014-11-17 |
2017-06-29 |
Genentech, Inc. |
Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
|
JP6771464B2
(ja)
|
2014-11-27 |
2020-10-21 |
ジェネンテック, インコーポレイテッド |
Cbpおよび/またはep300インヒビターとしての、4,5,6,7−テトラヒドロ−1h−ピラゾロ[4,3−c]ピリジン−3−アミン化合物
|
CA3081443A1
(en)
|
2014-12-15 |
2016-06-23 |
The Regents Of The University Of Michigan |
Small molecule inhibitors of egfr and pi3k
|
MX2017006864A
(es)
|
2014-12-23 |
2017-08-28 |
Genentech Inc |
Composiciones y métodos para tratar y diagnosticar cánceres resistentes a la quimioterapia.
|
EP3240908A2
(de)
|
2014-12-30 |
2017-11-08 |
F. Hoffmann-La Roche AG |
Verfahren und zusammensetzungen zur diagnose und behandlung von krebs
|
JP6659703B2
(ja)
|
2015-01-09 |
2020-03-04 |
ジェネンテック, インコーポレイテッド |
ピリダジノン誘導体および癌の処置におけるそれらの使用
|
JP6889661B2
(ja)
|
2015-01-09 |
2021-06-18 |
ジェネンテック, インコーポレイテッド |
4,5−ジヒドロイミダゾール誘導体およびヒストンジメチラーゼ(kdm2b)インヒビターとしてのその使用
|
JP6855379B2
(ja)
|
2015-01-09 |
2021-04-07 |
ジェネンテック, インコーポレイテッド |
癌の処置のためのヒストンデメチラーゼkdm2bのインヒビターとしての(ピペリジン−3−イル)(ナフタレン−2−イル)メタノン誘導体および関連化合物
|
JP6709792B2
(ja)
|
2015-01-29 |
2020-06-17 |
ジェネンテック, インコーポレイテッド |
治療用化合物およびその使用
|
CN107438593B
(zh)
|
2015-01-30 |
2020-10-30 |
基因泰克公司 |
治疗化合物及其用途
|
MA41598A
(fr)
|
2015-02-25 |
2018-01-02 |
Constellation Pharmaceuticals Inc |
Composés thérapeutiques de pyridazine et leurs utilisations
|
WO2016164480A1
(en)
|
2015-04-07 |
2016-10-13 |
Genentech, Inc. |
Antigen binding complex having agonistic activity and methods of use
|
IL255312B
(en)
|
2015-05-12 |
2022-08-01 |
Genentech Inc |
Therapeutic and diagnostic methods for cancer containing a pd–l1 binding antagonist
|
EP3708681A1
(de)
|
2015-05-29 |
2020-09-16 |
F. Hoffmann-La Roche AG |
Therapeutische und diagnostische verfahren für krebs
|
EP3303397A1
(de)
|
2015-06-08 |
2018-04-11 |
H. Hoffnabb-La Roche Ag |
Verfahren zur krebsbehandlung mit anti-ox40-antikörpern und pd-1-achsen-bindungsantagonisten
|
CN107810011A
(zh)
|
2015-06-08 |
2018-03-16 |
豪夫迈·罗氏有限公司 |
使用抗ox40抗体治疗癌症的方法
|
CA2986263A1
(en)
|
2015-06-17 |
2016-12-22 |
Genentech, Inc. |
Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
|
DK3341376T3
(da)
|
2015-08-26 |
2021-03-29 |
Fundacion Del Sector Publico Estatal Centro Nac De Investigaciones Oncologicas Carlos Iii F S P Cnio |
Kondenserede tricykliske forbindelser som proteinkinase-inhibitorer
|
CN108350605A
(zh)
|
2015-09-04 |
2018-07-31 |
台湾浩鼎生技股份有限公司 |
聚糖阵列以及使用方法
|
RU2732591C2
(ru)
|
2015-09-25 |
2020-09-21 |
Дженентек, Инк. |
Анти-tigit антитела и способы применения
|
WO2017106647A1
(en)
|
2015-12-16 |
2017-06-22 |
Genentech, Inc. |
Process for the preparation of tricyclic pi3k inhibitor compounds and methods for using the same for the treatment of cancer
|
TWI740873B
(zh)
*
|
2015-12-24 |
2021-10-01 |
日商協和麒麟股份有限公司 |
α、β不飽和醯胺化合物
|
CN108368179B
(zh)
|
2016-01-08 |
2022-08-23 |
豪夫迈·罗氏有限公司 |
使用pd-1轴结合拮抗剂和抗cea/抗cd3双特异性抗体治疗cea阳性癌症的方法
|
EP3402536A4
(de)
|
2016-01-13 |
2019-07-03 |
Hadasit Medical Research Services And Development Limited |
Radioaktiv markierte erlotinib-analoga und verwendungen davon
|
AU2017225854B2
(en)
|
2016-02-29 |
2020-11-19 |
Foundation Medicine, Inc. |
Therapeutic and diagnostic methods for cancer
|
AU2017239637A1
(en)
|
2016-03-29 |
2018-11-15 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
US10980894B2
(en)
|
2016-03-29 |
2021-04-20 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
WO2017180864A1
(en)
|
2016-04-14 |
2017-10-19 |
Genentech, Inc. |
Anti-rspo3 antibodies and methods of use
|
CA3019921A1
(en)
|
2016-04-15 |
2017-10-19 |
Genentech, Inc. |
Methods for monitoring and treating cancer
|
CN109154027A
(zh)
|
2016-04-15 |
2019-01-04 |
豪夫迈·罗氏有限公司 |
用于监测和治疗癌症的方法
|
WO2017180581A1
(en)
|
2016-04-15 |
2017-10-19 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
BR112018071683A2
(pt)
|
2016-04-22 |
2019-02-19 |
Obi Pharma, Inc. |
método para tratar um câncer de mama, método para tratamento de um tumor em um paciente, método para tratar um indivíduo sofrendo com câncer por imunoterapia, método para induzir/melhorar uma resposta imune em um indivíduo, método para melhorar a vacina obi-822 induzida pela resposta imune em um indivíduo necessitando da mesma, método para identificar um paciente adequado para terapia do câncer e método para determinar o prognóstico do tratamento do câncer ou resposta do fármaco de um paciente
|
US20190151346A1
(en)
|
2016-05-10 |
2019-05-23 |
INSERM (Institute National de la Santé et de la Recherche Médicale) |
Combinations therapies for the treatment of cancer
|
WO2017205536A2
(en)
|
2016-05-24 |
2017-11-30 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
WO2017205538A1
(en)
|
2016-05-24 |
2017-11-30 |
Genentech, Inc. |
Pyrazolopyridine derivatives for the treatment of cancer
|
DK3468997T3
(da)
|
2016-06-08 |
2023-10-02 |
Xencor Inc |
Behandling af IgG4-relaterede sygdomme med anti-CD9-antistoffer med tværbinding til CD32B
|
CN109312407A
(zh)
|
2016-06-08 |
2019-02-05 |
豪夫迈·罗氏有限公司 |
用于癌症的诊断和治疗方法
|
WO2018022933A1
(en)
|
2016-07-27 |
2018-02-01 |
Obi Pharma, Inc. |
Immunogenic/therapeutic glycan compositions and uses thereof
|
US11643456B2
(en)
|
2016-07-29 |
2023-05-09 |
Obi Pharma, Inc. |
Human antibodies, pharmaceutical compositions and methods
|
EP3494139B1
(de)
|
2016-08-05 |
2022-01-12 |
F. Hoffmann-La Roche AG |
Multivalente und multiepitopische anitikörper mit agonistischer wirkung und verfahren zur verwendung
|
CN109476748B
(zh)
|
2016-08-08 |
2023-05-23 |
豪夫迈·罗氏有限公司 |
用于癌症的治疗和诊断方法
|
KR20190072528A
(ko)
|
2016-10-06 |
2019-06-25 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
EP3532091A2
(de)
|
2016-10-29 |
2019-09-04 |
H. Hoffnabb-La Roche Ag |
Anti-mic-antikörper und verfahren zur verwendung
|
WO2018094414A1
(en)
|
2016-11-21 |
2018-05-24 |
Obi Pharma, Inc. |
Conjugated biological molecules, pharmaceutical compositions and methods
|
TW201837467A
(zh)
|
2017-03-01 |
2018-10-16 |
美商建南德克公司 |
用於癌症之診斷及治療方法
|
BR112019021411A2
(pt)
|
2017-04-13 |
2020-05-05 |
Hoffmann La Roche |
métodos para tratar ou retardar a progressão do câncer e para melhorar a função, usos de um imunoconjugado, de um agonista, de um antagonista, composições, kit e invenção
|
TWI823859B
(zh)
|
2017-07-21 |
2023-12-01 |
美商建南德克公司 |
癌症之治療及診斷方法
|
AU2018316343A1
(en)
|
2017-08-11 |
2020-02-13 |
Genentech, Inc. |
Anti-CD8 antibodies and uses thereof
|
AU2018329925A1
(en)
|
2017-09-08 |
2020-03-05 |
F. Hoffmann-La Roche Ag |
Diagnostic and therapeutic methods for cancer
|
CN107400094B
(zh)
*
|
2017-09-08 |
2020-04-03 |
贾玉庆 |
喹唑啉基羧酸酯类化合物及其用途
|
EP3710001A4
(de)
|
2017-10-27 |
2021-07-14 |
University Of Virginia Patent Foundation |
Verbindungen und verfahren zur regulierung, begrenzung oder hemmung der avil-expression
|
EP3707510B1
(de)
|
2017-11-06 |
2024-06-26 |
F. Hoffmann-La Roche AG |
Diagnose- und therapieverfahren für krebs
|
CR20200358A
(es)
|
2018-01-26 |
2021-02-22 |
Exelixis Inc |
Compuestos para el tratamiento de trastornos dependientes de cinasas
|
WO2019148043A1
(en)
|
2018-01-26 |
2019-08-01 |
Exelixis, Inc. |
Compounds for the treatment of kinase-dependent disorders
|
PE20210044A1
(es)
|
2018-01-26 |
2021-01-08 |
Exelixis Inc |
Compuestos para el tratamiento de trastornos dependientes de cinasas
|
CA3092108A1
(en)
|
2018-02-26 |
2019-08-29 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2019226514A2
(en)
|
2018-05-21 |
2019-11-28 |
Nanostring Technologies, Inc. |
Molecular gene signatures and methods of using same
|
CA3103017A1
(en)
|
2018-06-23 |
2019-12-26 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
TW202035444A
(zh)
|
2018-06-27 |
2020-10-01 |
台灣浩鼎生技股份有限公司 |
用於糖蛋白工程的糖苷合成酶變體及其使用方法
|
MX2021000558A
(es)
|
2018-07-18 |
2021-04-13 |
Genentech Inc |
Metodos para tratar el cancer de pulmon con un antagonista de fijacion al eje pd-1, un antimetabolito y un agente de platino.
|
WO2020051099A1
(en)
|
2018-09-03 |
2020-03-12 |
Genentech, Inc. |
Carboxamide and sulfonamide derivatives useful as tead modulators
|
WO2020061060A1
(en)
|
2018-09-19 |
2020-03-26 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
CA3111809A1
(en)
|
2018-09-21 |
2020-03-26 |
Genentech, Inc. |
Diagnostic methods for triple-negative breast cancer
|
WO2020068867A1
(en)
|
2018-09-25 |
2020-04-02 |
Black Diamond Therapeutics, Inc. |
Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use
|
CA3116324A1
(en)
|
2018-10-18 |
2020-04-23 |
Genentech, Inc. |
Diagnostic and therapeutic methods for sarcomatoid kidney cancer
|
CN109608334B
(zh)
*
|
2019-01-11 |
2021-07-13 |
盐城通海生物科技有限公司 |
一种合成4-甲氧基巴豆酸甲酯的方法
|
WO2020163589A1
(en)
|
2019-02-08 |
2020-08-13 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
JP2022521773A
(ja)
|
2019-02-27 |
2022-04-12 |
ジェネンテック, インコーポレイテッド |
抗tigit抗体と抗cd20抗体又は抗cd38抗体とによる処置のための投薬
|
CN113677994A
(zh)
|
2019-02-27 |
2021-11-19 |
外延轴治疗股份有限公司 |
用于评估t细胞功能和预测对疗法的应答的方法和药剂
|
WO2020223233A1
(en)
|
2019-04-30 |
2020-11-05 |
Genentech, Inc. |
Prognostic and therapeutic methods for colorectal cancer
|
WO2020226986A2
(en)
|
2019-05-03 |
2020-11-12 |
Genentech, Inc. |
Methods of treating cancer with an anti-pd-l1 antibody
|
CN112300279A
(zh)
|
2019-07-26 |
2021-02-02 |
上海复宏汉霖生物技术股份有限公司 |
针对抗cd73抗体和变体的方法和组合物
|
MX2022002738A
(es)
|
2019-09-04 |
2022-06-27 |
Genentech Inc |
Agentes de union a cd8 y uso de los mismos.
|
CN114787144A
(zh)
|
2019-09-26 |
2022-07-22 |
埃克塞里艾克西斯公司 |
吡啶酮化合物及用于调节蛋白激酶的方法
|
AU2020351734A1
(en)
|
2019-09-27 |
2022-04-14 |
Genentech, Inc. |
Dosing for treatment with anti-TIGIT and anti-PD-L1 antagonist antibodies
|
WO2021083949A1
(en)
|
2019-10-29 |
2021-05-06 |
F. Hoffmann-La Roche Ag |
Bifunctional compounds for the treatment of cancer
|
KR20220092580A
(ko)
|
2019-11-06 |
2022-07-01 |
제넨테크, 인크. |
혈액암의 치료를 위한 진단과 치료 방법
|
KR20220101138A
(ko)
|
2019-11-13 |
2022-07-19 |
제넨테크, 인크. |
치료적 화합물 및 사용 방법
|
AU2020403145A1
(en)
|
2019-12-13 |
2022-07-07 |
Genentech, Inc. |
Anti-Ly6G6D antibodies and methods of use
|
WO2021127404A1
(en)
|
2019-12-20 |
2021-06-24 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
TW202142230A
(zh)
|
2020-01-27 |
2021-11-16 |
美商建南德克公司 |
用於以抗tigit拮抗體抗體治療癌症之方法
|
WO2021177980A1
(en)
|
2020-03-06 |
2021-09-10 |
Genentech, Inc. |
Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
|
CN115698717A
(zh)
|
2020-04-03 |
2023-02-03 |
基因泰克公司 |
癌症的治疗和诊断方法
|
WO2021222167A1
(en)
|
2020-04-28 |
2021-11-04 |
Genentech, Inc. |
Methods and compositions for non-small cell lung cancer immunotherapy
|
AU2021293038A1
(en)
|
2020-06-16 |
2023-02-02 |
F. Hoffmann-La Roche Ag |
Methods and compositions for treating triple-negative breast cancer
|
IL298946A
(en)
|
2020-06-18 |
2023-02-01 |
Genentech Inc |
Treatment with anti-TIGIT antibodies and PD-1 spindle-binding antagonists
|
US20230266322A1
(en)
|
2020-06-30 |
2023-08-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapy and radical surgery
|
US20230235408A1
(en)
|
2020-06-30 |
2023-07-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies
|
CN111848584A
(zh)
*
|
2020-07-10 |
2020-10-30 |
江南大学 |
一种多取代喹唑啉类化合物及其应用
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
CN116568824A
(zh)
|
2020-08-03 |
2023-08-08 |
基因泰克公司 |
淋巴瘤的诊断和治疗方法
|
WO2022036146A1
(en)
|
2020-08-12 |
2022-02-17 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
CA3193273A1
(en)
|
2020-08-27 |
2022-03-03 |
Enosi Therapeutics Corporation |
Methods and compositions to treat autoimmune diseases and cancer
|
WO2022066805A1
(en)
|
2020-09-23 |
2022-03-31 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
CA3193952A1
(en)
|
2020-10-05 |
2022-04-14 |
Bernard Martin Fine |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
US20230107642A1
(en)
|
2020-12-18 |
2023-04-06 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
KR20230155422A
(ko)
|
2020-12-22 |
2023-11-10 |
메카니스틱 테라퓨틱스 엘엘씨 |
Egfr 및/또는 pi3k 억제제로서의 치환된 아미노벤질헤테로아릴 화합물
|
JP2024506339A
(ja)
|
2021-02-12 |
2024-02-13 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
がんの治療のための二環式テトラヒドロアゼピン誘導体
|
JP2024507794A
(ja)
|
2021-02-19 |
2024-02-21 |
エグゼリクシス, インコーポレイテッド |
ピリドン化合物および使用方法
|
JP2024515204A
(ja)
*
|
2021-04-22 |
2024-04-05 |
ボロノイ インコーポレイテッド |
ヘテロアリール誘導体化合物およびその用途
|
KR20240026948A
(ko)
|
2021-05-25 |
2024-02-29 |
에라스카, 아이엔씨. |
황 함유 헤테로방향족 트리사이클릭 kras 억제제
|
WO2022266206A1
(en)
|
2021-06-16 |
2022-12-22 |
Erasca, Inc. |
Kras inhibitor conjugates
|
CA3226019A1
(en)
|
2021-07-20 |
2023-01-26 |
Ags Therapeutics Sas |
Extracellular vesicles from microalgae, their preparation, and uses
|
TW202321261A
(zh)
|
2021-08-10 |
2023-06-01 |
美商伊瑞斯卡公司 |
選擇性kras抑制劑
|
CN115894455B
(zh)
*
|
2021-09-30 |
2024-04-19 |
北京赛特明强医药科技有限公司 |
一种喹唑啉类化合物、组合物及其应用
|
TW202332429A
(zh)
|
2021-11-24 |
2023-08-16 |
美商建南德克公司 |
治療性化合物及其使用方法
|
US20230203062A1
(en)
|
2021-11-24 |
2023-06-29 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
WO2023128350A1
(ko)
*
|
2021-12-30 |
2023-07-06 |
주식회사 비투에스바이오 |
헤테로아릴 유도체 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
|
WO2023144127A1
(en)
|
2022-01-31 |
2023-08-03 |
Ags Therapeutics Sas |
Extracellular vesicles from microalgae, their biodistribution upon administration, and uses
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
WO2024015897A1
(en)
|
2022-07-13 |
2024-01-18 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024020432A1
(en)
|
2022-07-19 |
2024-01-25 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024033388A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033458A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydroazepine derivatives
|
WO2024033457A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033389A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024085242A2
(en)
|
2022-10-21 |
2024-04-25 |
Kawasaki Institute Of Industrial Promotion |
Non-fouling or super stealth vesicle
|
WO2024088808A1
(en)
|
2022-10-24 |
2024-05-02 |
Ags Therapeutics Sas |
Extracellular vesicles from microalgae, their biodistribution upon intranasal administration, and uses thereof
|
WO2024091991A1
(en)
|
2022-10-25 |
2024-05-02 |
Genentech, Inc. |
Therapeutic and diagnostic methods for multiple myeloma
|